Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Targeted Oncology
Published in: Targeted Oncology 6/2017

01-12-2017 | Letter to the Editor

Comment on: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”

Author: Arnaud Uguen

Published in: Targeted Oncology | Issue 6/2017

Login to get access

Excerpt

I read with interest the recent article published in Targeted Oncology by Auliac et al. [1]. In addition to clinical trials data, it is always valuable to collect real-life data on the patients’ therapeutic management and follow-up. In this manner, the French retrospective analysis of patients with non-small cell lung cancer (NSCLC) harboring ALK rearrangements, led by Auliac et al., is of particular interest [1]. Nevertheless, besides clinical characteristics, disease management, and outcomes, the diagnostic criteria of the “ALK-positivity” of NSCLC and their potential impact on the patients’ outcomes, especially when treated with the anti-ALK tyrosine kinase inhibitor crizotinib, are not sufficiently taken into account in this study. …
Literature
1.
Auliac JB, Monnet I, Dubos-Arvis C, et al. Non-small cell lung cancer (NSCLC) harboring ALK translocations: clinical characteristics and management in a real-life setting: a French retrospective analysis (GFPC 02-14 study). Target Oncol. 2017; https://​doi.​org/​10.​1007/​s11523-017-0520-7.
2.
Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol. 2014;9(3):295–306.CrossRefPubMed
3.
Ilie MI, Bence C, Hofman V, et al. Discrepancies between FISH and immunohistochemistry for assessment of the ALK status are associated with ALK 'borderline'-positive rearrangements or a high copy number: a potential major issue for anti-ALK therapeutic strategies. Ann Oncol. 2015;26(1):238–44.CrossRefPubMed
4.
Lantuejoul S, Rouquette I, Blons H, et al. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas. Eur Respir J. 2015;46:207–18.CrossRefPubMed
5.
Uguen A, Andrieu-Key S, Vergne F, et al. ALK ambiguous-positive non-small cell lung cancers are tumors challenged by diagnostic and therapeutic issues. Oncol Rep. 2016;36(3):1427–34.CrossRefPubMed
6.
7.
van der Wekken AJ, Pelgrim R, ‘t Hart N, et al. Dichotomous ALK-IHC is a better predictor for ALK inhibition outcome than traditional ALK-FISH in advanced non-small cell lung cancer. Clin Cancer Res. 2017;23:4251–8.CrossRefPubMed
8.
Marchetti A, Di Lorito A, Pace MV, et al. ALK protein analysis by IHC staining after recent regulatory changes: a comparison of two widely used approaches, revision of the literature, and a new testing algorithm. J Thorac Oncol. 2016;11:487–95.CrossRefPubMed
9.
Metadata
Title
Comment on: “Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)”
Author
Arnaud Uguen
Publication date
01-12-2017
Publisher
Springer International Publishing
Published in
Targeted Oncology / Issue 6/2017
Print ISSN: 1776-2596
Electronic ISSN: 1776-260X
DOI
https://doi.org/10.1007/s11523-017-0533-2

Other articles of this Issue 6/2017

Targeted Oncology 6/2017 Go to the issue

Short Communication

Non-Small-Cell Lung Cancer (NSCLC) Harboring ALK Translocations: Clinical Characteristics and Management in a Real-Life Setting: a French Retrospective Analysis (GFPC 02–14 Study)

Original Research Article

A Multi-Arm Phase I Study of the PI3K/mTOR Inhibitors PF-04691502 and Gedatolisib (PF-05212384) plus Irinotecan or the MEK Inhibitor PD-0325901 in Advanced Cancer

Review Article

The Treatment Landscape and New Opportunities of Molecular Targeted Therapies in Gastroenteropancreatic Neuroendocrine Tumors

Review Article

Antibody–Drug Conjugates for the Treatment of Solid Tumors: Clinical Experience and Latest Developments

Review Article

The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions

Original Research Article

Comparative Safety of Targeted Therapies for Metastatic Colorectal Cancer between Elderly and Younger Patients: a Study Using the International Pharmacovigilance Database
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits